
This study elucidates the critical roles of tight junction proteins, such as CLDN18.2, in gastric cancer and various solid tumors, providing clear target selection and patient stratification strategies for tumor immunotherapy and antibody-drug conjugate development.
Literature Overview
This article, titled "Claudin proteins as emerging therapeutic targets for solid tumors," published in Nature Reviews Cancer, systematically explores the mechanisms of dysregulated expression, biological functions, and clinical translational potential of the Claudin family in solid tumors. The article provides a detailed review of how Claudin proteins transition from structural components maintaining epithelial cell polarity to key molecules driving tumor proliferation, metastasis, and drug resistance. It also focuses on the clinical progress of cutting-edge strategies targeting Claudin, including antibody drugs and CAR-T cell therapies.Background Knowledge
The Claudin protein family plays a central role in the structure of tight junctions. However, in solid tumors, they often exhibit abnormal overexpression or altered subcellular localization, leading to the loss of cell polarity and disruption of barrier function. The main challenges in current tumor therapy include the lack of highly specific surface antigens and drug resistance caused by tumor heterogeneity. As a specific biomarker in gastric cancer, research on CLDN18.2 faces bottlenecks in overcoming off-target toxicity to normal gastric mucosa and addressing expression heterogeneity within tumors. The functions of members such as CLDN1 and CLDN6 in liver and ovarian cancers are highly context-dependent, acting as both potential drivers and passive markers, which poses challenges for target validation in precision medicine. Furthermore, the correlation between immune infiltration in the tumor microenvironment and Claudin expression remains unclear, limiting the optimization of combination immunotherapies.
Research Methods and Core Experiments
The authors comprehensively analyzed genomic, transcriptomic, and proteomic data from The Cancer Genome Atlas (TCGA) and multiple public databases to systematically map the expression profiles of the Claudin family across various solid tumors. The study employed immunohistochemistry (IHC) to verify the non-junctional localization of proteins on the tumor cell surface and combined cell lines, organoids, and xenograft mouse models to deeply investigate the functional mechanisms of Claudin. Key evidence indicates that CLDN18.2 overexpression is closely associated with prognosis and immune cell infiltration in gastric cancer patients, while monoclonal antibodies targeting CLDN18.2 significantly inhibited tumor growth in preclinical models. Additionally, the study utilized gene editing technology to construct Claudin knockout or fusion models, revealing that the CLDN18-ARHGAP26 fusion gene drives the formation of signet ring cell carcinoma by activating the YAP signaling pathway.Key Conclusions and Perspectives
Research Significance and Prospects
This discovery has profound implications for drug development, particularly in advancing the research and development of bispecific antibodies, trispecific antibodies, and CAR-T cell therapies targeting CLDN18.2, CLDN1, and CLDN6. In terms of clinical monitoring, the study emphasizes the importance of accurately assessing Claudin expression levels and heterogeneity through IHC and liquid biopsy to guide patient stratification. For disease modeling, constructing mouse models carrying specific Claudin mutations or fusion genes will help more realistically simulate tumor development and evaluate the efficacy of novel therapies.
Conclusion
The Claudin protein family has evolved from traditional components of cell junction structures to key targets for solid tumor therapy, marking a new phase in precision oncology. This study not only elucidates the carcinogenic mechanisms of molecules such as CLDN18.2 and CLDN1 in gastric, liver, and ovarian cancers but also validates the feasibility of targeting strategies through clinical data. From laboratory mechanism analysis to clinical translation, Claudin-targeted therapies are expected to address current challenges in solid tumor treatment, such as drug resistance and recurrence. Future research needs to focus further on overcoming tumor heterogeneity, optimizing combination treatment regimens, and deeply analyzing the interaction network between Claudin and the tumor microenvironment, thereby providing a more efficient and safer care system for cancer patients and establishing Claudin-targeted drugs as a cornerstone of solid tumor therapy.

